BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19747832)

  • 1. Design, synthesis and biological evaluation of tripeptide boronic acid proteasome inhibitors.
    Zhu Y; Yao S; Xu B; Ge Z; Cui J; Cheng T; Li R
    Bioorg Med Chem; 2009 Oct; 17(19):6851-61. PubMed ID: 19747832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, in vitro and in vivo biological evaluation, docking studies, and structure--activity relationship (SAR) discussion of dipeptidyl boronic acid proteasome inhibitors composed of beta-amino acids.
    Zhu Y; Zhu X; Wu G; Ma Y; Li Y; Zhao X; Yuan Y; Yang J; Yu S; Shao F; Li R; Ke Y; Lu A; Liu Z; Zhang L
    J Med Chem; 2010 Mar; 53(5):1990-9. PubMed ID: 20158184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, biological evaluation, and structure-activity relationship (SAR) discussion of dipeptidyl boronate proteasome inhibitors, part I: comprehensive understanding of the SAR of alpha-amino acid boronates.
    Zhu Y; Zhao X; Zhu X; Wu G; Li Y; Ma Y; Yuan Y; Yang J; Hu Y; Ai L; Gao Q
    J Med Chem; 2009 Jul; 52(14):4192-9. PubMed ID: 19537716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of boronic acid derivatives of tyropeptin: proteasome inhibitors.
    Watanabe T; Momose I; Abe M; Abe H; Sawa R; Umezawa Y; Ikeda D; Takahashi Y; Akamatsu Y
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2343-5. PubMed ID: 19307118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, in vitro and in vivo biological evaluation, and comprehensive understanding of structure-activity relationships of dipeptidyl boronic acid proteasome inhibitors constructed from β-amino acids.
    Zhu Y; Wu G; Zhu X; Ma Y; Zhao X; Li Y; Yuan Y; Yang J; Yu S; Shao F; Lei M
    J Med Chem; 2010 Dec; 53(24):8619-26. PubMed ID: 21077681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibitors; synthesis and activity of arecoline oxide tripeptide derivatives.
    Marastoni M; McDonald J; Baldisserotto A; Canella A; De Risi C; Pollini GP; Tomatis R
    Bioorg Med Chem Lett; 2004 Apr; 14(8):1965-8. PubMed ID: 15050638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationship of boronic acid derivatives of tyropeptin: proteasome inhibitors.
    Watanabe T; Abe H; Momose I; Takahashi Y; Ikeda D; Akamatsu Y
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5839-42. PubMed ID: 20727746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacophore modeling, docking studies, and synthesis of novel dipeptide proteasome inhibitors containing boron atoms.
    Lei M; Zhao X; Wang Z; Zhu Y
    J Chem Inf Model; 2009 Sep; 49(9):2092-100. PubMed ID: 19691298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of new vinyl ester pseudotripeptide proteasome inhibitors.
    Marastoni M; Baldisserotto A; Trapella C; Gavioli R; Tomatis R
    Eur J Med Chem; 2006 Aug; 41(8):978-84. PubMed ID: 16713026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel CADD-based peptidyl vinyl ester derivatives as potential proteasome inhibitors.
    Mou K; Xu B; Ma C; Yang X; Zou X; Lü Y; Xu P
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2198-202. PubMed ID: 18280155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a potent and rapidly reversible inhibitor of the 20S-proteasome.
    Purandare AV; Wan H; Laing N; Benbatoul K; Vaccaro W; Poss MA
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4701-4. PubMed ID: 15324891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibitors for cancer therapy.
    Iqbal M; Messina McLaughlin PA; Dunn D; Mallya S; Husten J; Ator MA; Chatterjee S
    Bioorg Med Chem; 2012 Apr; 20(7):2362-8. PubMed ID: 22377673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel organic proteasome inhibitors identified by virtual and in vitro screening.
    Basse N; Montes M; Maréchal X; Qin L; Bouvier-Durand M; Genin E; Vidal J; Villoutreix BO; Reboud-Ravaux M
    J Med Chem; 2010 Jan; 53(1):509-13. PubMed ID: 19919035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.
    Rydzewski RM; Burrill L; Mendonca R; Palmer JT; Rice M; Tahilramani R; Bass KE; Leung L; Gjerstad E; Janc JW; Pan L
    J Med Chem; 2006 May; 49(10):2953-68. PubMed ID: 16686537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
    Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic studies of the branched chain amino acid preferring peptidase activity of the 20S proteasome: development of a continuous assay and inhibition by tripeptide aldehydes and clasto-lactacystin beta-lactone.
    McCormack TA; Cruikshank AA; Grenier L; Melandri FD; Nunes SL; Plamondon L; Stein RL; Dick LR
    Biochemistry; 1998 May; 37(21):7792-800. PubMed ID: 9601040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
    Suzuki N; Suzuki T; Ota Y; Nakano T; Kurihara M; Okuda H; Yamori T; Tsumoto H; Nakagawa H; Miyata N
    J Med Chem; 2009 May; 52(9):2909-22. PubMed ID: 19419205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3D-QSAR studies on tripeptide aldehyde inhibitors of proteasome using CoMFA and CoMSIA methods.
    Zhu YQ; Pei JF; Liu ZM; Lai LH; Cui JR; Li RT
    Bioorg Med Chem; 2006 Mar; 14(5):1483-96. PubMed ID: 16256351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.
    Fujita T; Doihara H; Washio K; Ino H; Murakami M; Naito M; Shimizu N
    Anticancer Drugs; 2007 Jul; 18(6):677-86. PubMed ID: 17762396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.
    Vispé S; Vandenberghe I; Robin M; Annereau JP; Créancier L; Pique V; Galy JP; Kruczynski A; Barret JM; Bailly C
    Biochem Pharmacol; 2007 Jun; 73(12):1863-72. PubMed ID: 17391647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.